FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to the chemical-pharmaceutical industry, and represents using a biologically active agent for preparing a drug for metabolic disorders specified in a group consisting of insulin resistance syndrome and diabetes mellitus, including type I diabetes mellitus and type II diabetes mellitus, and obesity, wherein the agent represents a compound of formula
,
wherein n=1 or 2; m=0, 1, 2, 4 or 5; q=0; t=0 or 1; R3 represents hydrogen; A is phenyl, unsubstituted or substituted by 1 or 2 alkyls having 1 or 2 carbon atoms; and R1 is hydrogen or alkyl having 1 or 2 carbon atoms; or when R1 represents hydrogen - a pharmaceutically acceptable salt of the compound.
EFFECT: preparing the drug for metabolic disorders.
18 cl, 6 ex, 22 tbl
Title | Year | Author | Number |
---|---|---|---|
COMPOUNDS FOR METABOLIC DISORDER TREATMENT | 2004 |
|
RU2358722C2 |
COMPOUNDS FOR TREATMENT OF METABOLIC DISORDERS | 2006 |
|
RU2420276C2 |
TETRAZOLE COMPOUNDS FOR REDUCING CONCENTRATION OF URIC ACID | 2009 |
|
RU2522458C2 |
COMPOUNDS AND METHODS FOR URIC ACID REDUCTION | 2009 |
|
RU2501554C2 |
COMPOUNDS FOR TREATING METABOLIC DISEASES | 2008 |
|
RU2502723C2 |
COMPOUNDS AND METHODS FOR URIC ACID REDUCTION | 2009 |
|
RU2501555C2 |
COMPOUNDS FOR TREATMENT OF METABOLIC DISEASES | 2002 |
|
RU2341513C2 |
COMPOUNDS FOR METABOLIC DISORDER TREATMENT | 2004 |
|
RU2349584C2 |
NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | 2010 |
|
RU2567755C2 |
DERIVATIVES OF DIARYLIC ACID AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 2000 |
|
RU2267484C2 |
Authors
Dates
2014-06-27—Published
2008-12-24—Filed